Merck & Co., Inc.

CIK 0000310158 · Q2 2026

13F Equity AUM

$526.4M

+50.6% QoQ

Positions

-1 QoQ

AUM Rank

#4,790

Top 38%

Skill Alpha (FF)

—

Building track record (6q)

Quarters Tracked

~1 years

Portfolio Concentration

Top 5: 93.3%Top 10: 99.8%Top 20: 100.0%

PSNL35.8%

MRNA30.7%

KYMR16.8%

AKTIS ONCOLOGY INC5.8%

EIKON THERAPEUTICS INC4.1%

TRDA2.4%

STRO1.7%

ALEC1.4%

EVAX0.7%

VRDN0.3%

HHI (Herfindahl-Hirschman Index) measures portfolio concentration. Low (<1500) = diversified, Moderate (1500-2500), High (>2500) = concentrated bets.

Sector Allocation

Healthcare89.8%

Unclassified10.2%

Portfolio weight by GICS sector based on latest 13F filing. Sectors below 2% are grouped as “Other.”

Position Sizing

Positions: 13Median: 1.72%Avg: 7.69%

0–0.5%

4(0.5%)

0.5–1%

1(0.7%)

1–3%

3(5.5%)

3–5%

1(4.1%)

5%+

4(89.1%)

Count of positions per weight bucket — (%) = combined portfolio weight

Loading summary cards...

Portfolio Overlap

Shared: 0Unique: 13vs 20 funds

0%Low

Fund positions

Consensus CUSIPs

Jaccard similarity of this fund’s portfolio vs the consensus of top 20 funds by AUM. Low (<15%) = contrarian, Moderate (15-40%), High (>40%) = follows the crowd.

Loading overlap analysis...

Position Changes This Quarter

New3Increased0Decreased0Exited4

New Positions

TRDA2.4%

+1.7M

STRO1.7%

+272K

EVAX0.7%

+1.2M

Exited

-1,739,768

-272,351

-1,214,126

-1,473,240

Quarter-over-quarter changes compared to prior 13F filing. New = first appearance; Exited = no longer held.

Loading position changes...

Holdings

Loading holdings...